The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%. This report contains:

• Descriptions of diabetes therapeutics including drugs for diabetes and diabetes complications, diabetes diagnostics including blood glucose testing devices and supplies, and all other interventions
• The current global market status for diabetes therapeutics and diagnostics, with trends and forecasts for growth over the next 5 years
• Technological issues including the latest trends and a thorough patent analysis
• Discussion of predictions of a type II diabetes global epidemic
• Company profiles.

The U.S. blood market was worth $7.8 billion in 2007. It should reach $9.5 million by 2012, a compound annual growth rate (CAGR) of 5.7%. This report contains:

• Descriptions of various types of blood and plasma collection and transfusion technologies including autologous donations, apheresis, fractionation, blood salvage and stem cells, and major plasma products such as coagulation factors, human serum albumin
• The current U.S. blood industry market status, with trends and forecasts for growth over the next 5 years
• Technological issues including the latest trends and a thorough patent analysis
• Analysis of federal regulations concerning blood supply and management
• Discussion of the international markets for various blood and blood-related products.

The global market for pharmacy automation increased from $2.1 billion in 2006 to $2.3 billion in 2007. It should reach $3.6 billion by 2012, a compound annual growth rate (CAGR) of 9.4%. This report contains:

• Descriptions of various pharmacy automation products for inpatient pharmacy automation settings including acute care and long-term care and outpatient pharmacy automation settings including fast-track, hospital retail, mail order and retail pharmacies
• The current global market status for pharmacy automation, with trends and forecasts for growth over the next 5 years
• Analysis of the pharmacy automation industry on a worldwide basis, both from market and application perspectives
• The latest technological advancements along with a thorough patent analysis
• Profiles of leading companies in pharmacy automation including Pyxis Corp, Parata Systems, McKesson and ScriptPro.

The global market for vaccines is expected to reach $20 billion by the end of 2008. It should reach $34 billion by 2013, a compound annual growth rate (CAGR) of nearly 11%. This report contains:

• Descriptions of various human and veterinary vaccines that treat infectious diseases, chronic infections, cancer, auto-immune diseases, allergies, high blood pressure and addictions
• The current market status of the vaccine industry, with trends and forecasts for growth over the next 5 years
• The latest vaccine research findings in prophylactic and therapeutic areas
• Analysis of significant vaccine-related patents in the Unites States and Europe
• An overview of the regulatory environment.

Advances in healthcare technology have extended the lifetimes and improved the quality of life of millions of people. Global markets for healthcare technology will continue to grow very strongly for the foreseeable future; as other technology markets mature and experience slower growth - or no growth at all - technologies used in healthcare continue to expand at robust rates. This review includes highlights of reports published by BCC Research on the following healthcare technology markets:

• Biocompatible Materials for the Human Body
• Advanced Orthopedic Technologies, Implants and Regenerative Products
• Microelectronic Medical Implants: Products, Technology & Opportunities
• The Global Market for Pain Management Drugs and Devices
• Medical Imaging: Equipment and Related Products
• The Home Medical Equipment Market.

The global market for telemedicine increased from $4.8 billion in 2006 to an estimated $5.8 billion in 2007. It should reach $13.9 billion by 2012, a compound annual growth rate (CAGR) of 19%. This report contains:

• Descriptions of various telemedicine technologies including hardware, software, telecom and network applications
• The current market status for telemedicine, trends and forecasts for growth over the next 5 years
• Discussion of cutting edge technology development, value-added services, and newer applications
• Thorough analyses of 91 patents
• Information about industry players, their strategic directives, product portfolios, and operational presence.

The global market for cardiovascular diagnostics and therapy increased from $111 billion in 2006 to an estimated $119.8 billion in 2007. It should reach $192.4 billion through 2012, a compound annual growth rate (CAGR) of 9.9%. This report contains:

• Descriptions of various types of cardiovascular diagnostics such as in vitro tests and in vivo imaging techniques, devices such as drug eluting stents, and drugs such as Pfizer's blockbuster Lipitor
• The current market status of cardiovascular diagnostics, devices and drugs, along with trends and forecasts for growth over the next 5 years
• Technological issues including the latest developments and a thorough patent analysis
• Analysis of the cardiovascular diagnostics, devices and drugs industry, both from a market and application perspective
• Information about the major players in each market, including Medtronic and Boston Scientific in devices, Sanofi-Aventis and BMS in drugs, and Abbott in devices.

The global market for blood disorder treatments increased from $34.8 billion in 2006 to an estimated $36.7 billion by the end of 2007. It should reach nearly $44.0 billion by 2012, a compound annual growth rate (cagr) of 3.9%. This report contains:

• Descriptions of various types of blood disorder treatments for anemia, hemophilia, neutropenia and thrombosis
• The current market status of blood disorder treatments, trends and forecasts for growth over the next 5 years
• Discussion of new technologies with a thorough patent analysis
• Analysis of the major overhaul of the U.S. Food and Drug Administration's approval process for blood disorder treatments
• Profiles of major players in the blood disorder treatment market.

The global home medical equipment market increased from about $13.9 billion in 2006 to an estimated $14.6 billion in 2007. It should reach $20.4 billion by 2012, a compound annual growth rate (CAGR) of 6.8%. This report contains:

• Descriptions of the main types of home medical equipment (HME) that have been commercialized to date including assistive devices, therapeutic devices, monitors, sensors and telemetry devices
• The current market status of HME, trends and forecasts for growth over the next 5 years
• A discussion of novel technologies along with a thorough patent analysis
• An evaluation of regulatory factors that will drive future demand in the industry
• Information about major manufacturers and distributors of HME.

The U.S. market for medical imaging equipment increased from $6.7 billion in to an estimated $7.8 billion in 2007. It should reach $11.6 billion in 2012, a compound annual growth rate (CAGR) of 8.1%. This report contains:

• Descriptions of various types of medical imaging equipment including x-ray, computed tomography and magnetic resonance imaging, and current and potential applications for each
• The current market status of medical imaging equipment, trends and forecasts for growth over the period 2007 through 2012
• Technological issues, including a patent analysis and a review of the latest developments
• Analysis of the industry's structure and regulatory environment
• Profiles of many of the leading companies in the industry.

The global orphan drugs market reached $58.7 billion in 2006, growing by 8% from $54.5 billion in 2005. It is expected to grow at a compounded annual growth rate (CAGR) of 7% to reach $81.8 billion by 2011. This report contains:

• An overview of orphan drug criteria, the history of Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends
• Detailed discussion of successful orphan products and a discussion of specific rare diseases for which orphan drugs exist
• Analysis of most promising therapeutic areas in the industry and leading orphan dugs in these therapeutic areas
• Global sales projections through 2011 for as many as 50 orphan drugs with sales exceeding $200 million
• Profiles of key players in the market and their market shares
• Technology trends analysis within orphan drugs market.

The U.S. market for medical waste treatment, containment, management and disposal increased from $1.9 billion in 2006 to an estimated $2.0 billion by the end of 2007. It should reach $2.6 billion by 2012, a compound annual growth rate of 5.1%. This report contains:

• Descriptions of various types of medical waste treatment, containment, management and disposal products, with current and potential applications for each
• The current market status of medical waste treatment, containment, management and disposal products and forecasts of growth over the next 5 years
• Technological issues, including the latest developments
• A discussion of the increased regulatory requirements for incineration methods and an overview of services and containment options used by health care companies in the United States
• An examination of the risks of contact with medical waste.

The global catheter market is estimated at $13.0 billion for 2007 and forecast to grow at a compound annual growth rate (CAGR) of 8.3% to reach $19.4 billion by 2012. This report contains:

• Descriptions of catheter technologies and their potential applications
• The current global market status of catheters, trends, and forecasts for growth over the next 5 years
• Technological issues, including the latest developments
• A discussion of regulatory issues affecting the current market and their potential impact on future markets
• Profiles of major manufacturers/suppliers of catheter technologies.

The global pain-management market is worth around $30.9 billion in 2007. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.63% to reach $40.6 billion by the end of the forecast period, 2012. This report contains:

• The major types of pain-management methods, including drugs (non-opioids, opioids, anticonvulsants, and antidepressants) and devices (transcutaneous electrical nerve stimulation (TENS), spinal cord stimulator (SCS), peripheral nerve stimulator (PNS), and intrathecal pumps)
• Analysis of each type of pain-relief technique, determining its current market status, its impact on future markets, and growth over the 5-year period 2007 through 2012
• Technological issues, including the latest trends, plus other influential factors, such as patents, new products, and other adjuvant techniques of pain management.

China sold approximately $9.2 billion worth of medical equipment in 2006, an increase of 12.2% over 2005. This trend is expected to continue albeit at a reduced rate. This report contains:

• An overview providing definitions, market entry strategies, best sales prospects, and important regulations for the Chinese medical equipment industry
• Product types (imaging diagnostic equipment, patient monitoring equipment, and clinical diagnostic laboratory instruments), with analyses the Chinese market's dynamics, and market shares, along with company profiles.
• Market projections through 2012
• A discussion on end users, focusing on the Chinese population and demographics as well as an analysis of the Chinese healthcare system
• International aspects of the market such as imports, exports, and international players
• An analysis of China's technology and major patents.

The global market for microelectronic medical implants was worth an estimated $11.7 billion in 2006. The market is projected to grow to $12.6 billion in 2007 and $22.1 billion in 2012 at a CAGR of 11.9% from 2007 to 2012. This report contains:

• Major implant types and applications, both commercial and developmental
• Global market size and segmentation, including historical data on sales by application and implant type
• Market drivers and constraints.
• Detailed market projections through 2012
• Industry structure, competition, and market shares
• Factors that may influence the long-term market for microelectronic implants.

The medical membrane device market, including dialyzers, blood oxygenators, IV filters and blood/apheresis filters, is valued at nearly $1.8 billion in 2007 and is increasing at a compound annual growth rate (CAGR) of 5.3% to reach $ 2.3 billion in 2012. This report contains:

• Industry structure covering, membrane device manufacturers, technology companies, distribution channels, and customers
• Company profiles
• Medical membrane device technology
• Patent analysis
• History, overview, company sales and five-year market forecasts for the following five product areas: hemodialyzers, blood oxygenators, IV filters, diagnostic devices and blood microfilters

The total market for advanced orthopedic technology and products was estimated to exceed $17.5 billion in 2006, up 11.7% from $15.7 billion the previous year (2005). By 2012, the advanced orthopedic technology and product market is likely to reach $31.9 billion, with average growth estimated at 10.3%. This report:

• Provides a complete U.S. and global market analysis
• Quantifies all major markets, including bone repair and regenerative products, cartilage repair and regenerative products, joint replacements, implants and regenerative products, tissue repair and regenerative products, and others
• Analyzes key market drivers such as insurance and reimbursement issues, marketing and advertising issues and trends, world demographics, the trends in orthopedic disability and evolving lifestyles trends, orthopedic-device related infections and much more
• Includes industry overview, development of the advanced orthopedic market, regulation and classification of devices by region
• Analyzes markets by product type, competitor analysis and supplier strategy, research and development, patent analysis, and company profiles are all included in this comprehensive volume.

The U.S. market for biocompatible materials is valued at $ 22.2 billion in 2007 and is expected to grow with a compound annual growth rate (CAGR) of 6.9% to reach $30.9 billion in 2012. This report contains:

• An examination of the supporting products that have enhanced imaging at the chemical level (reagents and contrast media) and at the analysis level (software tools and image management)
• The U.S. markets for medical devices, tissue replacements, and surface coating biomaterials for a variety of biomaterials categories including metals, ceramics, polymers, and natural materials
• Assessment of the market for specific medical applications including orthopedic surgery, cardiovascular surgery and care, wound management, dentistry, urology, gastrointestinal surgery, ophthalmic care as well as plastics and reconstructive surgery
• A review of important technology and a discussion of patents in the past few decades
• Profiles of all the major companies in the industry.

The global market for neurological disease treatment and medication was worth $12.6 billion in 2006 and will reach $14 billion by 2007. At a compound annual growth rate (CAGR) of 11.6%, the global market will be worth almost $24.3 billion by 2012. This report contains:

• An analysis of the trends in drug discovery and development for the neurodegenerative disorders
• An overview of the global neurological disorders treatment market which provides definitions and a structure for the industry
• Provides details for the treatment markets of specific diseases such as Alzheimer's, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, muscular dystrophy, and other, rarer neurological disorders
• Offers a detailed analysis of patents as well as important technological developments
• A review of government regulations
• Profiles the most important companies in the industry today.

The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%. This report contains:

• An examination of the major markets for antifungal applications in human healthcare, veterinary healthcare, agriculture and the environment/buildings
• Analysis of each market segment on the global level, with current market status, and forecasts for growth over the next five years to 2012
• Highlights and reviews of FDA restrictions, government legislation, as well as discussions on fungal resistance and changes in consumer preferences, such as a greater demand for OTC medications and/or natural and alternative remedies
• Presentation of new drug and patent applications, new methods of drug administration, drug discovery and development, and various clinical trials and applications
• Profiles for important companies

The global market for immunotherapies to treat cancer was worth $19.6 billion in 2006 and will reach $23.7 billion by the end of 2007. At a compound annual growth rate (CAGR) of 9.5%, the global market will be worth more than $37.2 billion by 2012. This report contains:

• Analyses of products and applications in the cancer immunotherapy sector, including biological response modifiers (cytokines), monoclonal antibody-based products, therapeutic vaccines and other cancer immunotherapies.
• An overview of the global market, including historical data for cancer treatment and therapies, the latest market trends, and 5-year forecasts and estimates through 2012
• A section on industry structure with strategies employed by Big Pharma as well as top-selling drug patent expirations and how this relates to the overall pharmaceutical industry and biotechnology companies in particular
• Sections on products and applications with synopses of more than 100 cancer immunotherapy drug and vaccine products, including those currently marketed and those in Phase III or later development
• Analyses of patents within the past few decades
• Profiles for important businesses.

The U.S. in vitro toxicity (predictive toxicity) testing market has been valued at $765 million in 2006. At a compound annual growth rate (CAGR) of 14.4%, the total U.S. market will grow to reach $1.5 billion by 2011. This report contains:

• An overview of the in-vitro toxicology testing market, explaining basic principles and practices, definitions, classes of tests, and the different types of toxicology
• A technical overview that describes toxicology testing strategies, the various toxicology categories, and alternatives to the standard toxicology methods
• An in-depth review of the current market status, historical market data, compound annual growth rates, and forecasts to 2011
• Information on specific technology in the markets, including revenues and developments
• A thorough analysis of patents and profiles of the major players.

The global market for prescription endocrine and metabolic disease drugs was $66.2 billion in 2005 and $72.3 billion in 2006. At a compounded annual growth rate (CAGR) of 5.2%, the market will reach $96.4 billion by 2011. This report contains:

• The major current and emerging markets for prescription drugs for endocrine and metabolic diseases, including hypertension, infertility, thyroid diseases, hypercholesterolemia, and obesity
• Historical market data from 2004, 2005, and 2006, in addition to five-year market forecasts with compounded annual growth rates through 2011
• Discusses applications as well as current and upcoming technology and trends
• Provides detailed patent analysis and profiles of the major companies in the biotechnology and pharmaceutical industries that provide products for the diseases covered in this report.

The total U.S. market for advanced wound care technologies was worth more than $2.3 billion in 2005. By the end of 2006 the market will reach almost $2.6 billion, and over a five-year period will grow at an average annual growth rate (AAGR) of 12.3% to reach $4.6 billion in 2011. This report:

• Provides an analysis of and quantitative market forecast for advanced wound care products, including wound types by demographic category.
• Covers all key market segments: acute wounds, chronic wounds, and burn wounds. The markets for biological dressings; surgical sealants and glues; synthetic dressings; other wound healing products; and wound healing devices are all analyzed and forecasts provides to 2012.
• Includes all significant wound care consumables and wound-healing devices.
• Includes detailed market analysis and competitive analysis, and information about significant products, players, issues and trends, and other information affecting the wound care industry.
• Includes industry structure, market shares, company profiles and patent analysis.

The U.S. market for medical imaging reagents and analysis tools is valued at a little more than $4.9 billion in 2006 and is expected to grow at an average annual growth rate of 11.9% to reach over $8.4 billion in 2011. This report contains:

• A detailed analysis of medical imaging, including supporting products that have enhanced imaging at the chemical (reagents and contrast media) and analytical (software tools and image management) levels
• Regulatory aspects important to the industry
• Market forecasts based on historical and current data, with five-year projections to 2011, including the U.S. market for medical imaging by technology, and the U.S. market for imaging products, by medical application
• An examination of existing technology, the latest innovations and important patents
• Profiles of the top companies within the industry.

The U.S. medical plastics market will reach almost 2.7 billion pounds by the end of 2006 and will grow at an average annual growth rate (AAGR) of 4.4%, consuming over 3.3 billion pounds by 2011. This report contains:

• An initial treatment of the U.S. medical device industry, with a comprehensive overview of the current market and definitions
• Detailed forecasts for the U.S. market through 2011
• Recent and upcoming legislation and regulatory issues and concerns for the medical plastics in medical devices
• Profiles for the top players in the market today
• A details patent analysis.

The worldwide global market for bioactive materials increased from $377.7 million in 2004 to $431.4 million in 2005 with sales reaching an estimated $473.9 million by the end of 2006. Sales of glasses, glass-ceramics, and ceramics represent the largest share of this market. At an average annual growth rate (AAGR) of 17.2%, this market will cross $1.0 billion by 2011. This report:

• Describes various types of bioactive materials (i.e., glasses, glass-ceramics, ceramics, and composites), their fabrication methods (including variants and upgrades), and identifies current and potential applications for each type
• Analyzes the bioactive materials industry on a worldwide basis from the standpoint of both manufacturing and consumption, with detailed forecasts to 2011
• Examines commercial and public research activities in major regions of the world
• Profiles the top companies in the industry and offers an in-depth patent analysis.

The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011. This report contains:

• An overview of the major types of drug delivery systems used in the health industry
• Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
• Discussion of the technological issues, including the latest trends and developments
• Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
• Profiles of the major players within the industry and a detailed patent analysis.

The global market for herbal supplements was $5.5 billion in 2005 and $5.6 billion by the end of 2006. Growing at an average annual growth rate (AAGR) of 1.7%, this market sector will cross just over $6.1 billion by 2011. This report contains:

• The major current and emerging markets for herbal supplements, prescription drugs and (where applicable) OTC treatments
• An overview section that provides a discussion of the emergence of the herbal supplements market, U.S. and overseas regulations and guidelines relating to this market, sources of raw materials and concerns about sustainability of herbal harvesting practices
• A global forecast for the herbal supplement and OTC market, with a five-year forecast date to 2011
• The latest company profiles for the top companies in the market
• A detailed patent analysis.

BCC estimates the U.S. healthcare IT market size at $16.38 billion in 2005 and forecasts that it will grow to $18.5 billion in 2006. By 2011 it is expected to reach $34.7 billion in sales, a 13.4% AAGR. This report contains:

• The market for healthcare information technology in the U.S., providing an overview of the healthcare IT market
• Current and future market estimates for healthcare information systems with a detailed analysis of trends and market size and forecasts through 2011
• Highlights upcoming and emerging technologies, as well as new developments that are likely to impact the future of the market
• Business activities on the entire major market players and a detailed profile of the top companies in the industry.

The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011. This report contains:

• A thorough evaluation of the U.S. prescription ophthalmic pharmaceutical, device, diagnostic, and surgical market, with forecasts to 2011
• Market analysis focused on specific diseases and conditions such as cataract, glaucoma and refractive treatments
• Information regarding incidence and prevalence of eye conditions and risk factors associated with those conditions
• Examination of research and development activities with an emphasis on segments offering benefits to aging populations
• Profiles of the major companies in the industry as well as a detailed patent analysis.

U.S. market revenues for IV therapy and vein access were worth more than $4.6 billion in 2005. At an average annual growth rate (AAGR) of 4.2%, the market will reach almost $5.7 billion by 2010. This report contains:

• An in-depth look at the market for I.V. therapy and vein access in the United States market
• An extensive overview of the industry, its relationship to the healthcare industry and its participants, and trends for the future
• Competitive and market analyses, which historical data and market forecasts to 2010
• Detailed company profiles of all the major players in the I.V. therapy and vein access industry.

Spending for clinical trials in the U.S. was nearly $24 billion in 2005. By 2006 this number will rise to $25.6 billion and then $32.1 billion in 2011, an average annual growth rate (AAGR) of 4.6%. This report contains:

• An overview of clinical development phases, the regulatory issues involved and the factors influencing clinical trial costs
• An in-depth analysis of the U.S. market for clinical trials that reviews historical data, market trends, and forecasts through 2011
• Highlights for new and upcoming technologies and developments that could have an impact on the clinical trials business
• Profiles of the major players in the business.

The U.S. market for medical robotics and computer-assisted surgical equipment was worth an estimated $564 million in 2005. The market is projected to reach $704 million in 2006 and $2.8 billion by 2011, an average annual growth rate (AAGR) of 31.4%. This report:

• Identifies and segments the main types of MRCAS devices commercialized to date.
• Analyzes the historical and current volume and value of these product segment shipments in specified applications and geographical markets.
• Identifies and evaluates the impact of demographic, economic and other factors that will drive future demand for MRCAS devices.
• Forecasts the U.S. volume and value of shipments of the product segments for the period 2006 through 2011
• Identifies promising new surgical procedures and products still in the development and testing stage, and assesses and forecasts their potential market size.
• Identifies leading manufacturers of the devices and analyzes the structure of the MRCAS industry (e.g., market shares, concentration, recent M&A activity).
• Assesses the long-term outlook for MRCAS equipment, taking into account market opportunities as well as technological, financial, and economic factors.

The global market for MIS devices and instruments was worth an estimated $12 billion in 2005, and is expected to reach $12.9 billion in 2006 and $18.5 billion by 2011, an AAGR of 7.5% between 2006 and 2011. This report:

• Identifies and segments the main types of minimally invasive devices and instruments that have been commercialized to date,
• Analyzes the historical and current volume and value of shipments of each of these product segments in specified end-user and geographical markets,
• Evaluates the impact of demographic, economic and other factors that will drive future demand for minimally invasive devices,
• Forecasts the volume and value of shipments of the product segments,
• Assesses promising surgical procedures and products in development, and forecasts their potential market,
• Identifies leading manufacturers of the devices and analyzes the structure of the minimally invasive surgical devices industry,
• Assesses the long-term outlook for the industry.

The U.S. market for patient monitoring devices and related consumable supplies was worth an estimated $4.3 billion in 2005. The market is projected to grow to $4.6 billion in 2006 and $6.3 billion by 2011, an average annual growth rate (AAGR) of 6.6%. This report:

• Identifies and segments the main types of patient monitoring devices commercialized to date.
• Analyzes the historical and current value of each of these product segments in specified applications and end-user markets.
• Evaluates the impact of demographic, technological, regulatory and other factors that will drive future demand in each of these segments.
• Forecasts the value of future shipments in each segment.
• Identifies new technologies and products still in the development and testing stage that are likely to be commercialized successfully in the next five years
• Details leading vendors of patient monitoring devices and related equipment and analyzes industry structure (e.g., market shares, concentration, recent M&A activity).

The value of worldwide sales for all categories of coatings and surface treatment processes used in manufacturing medical devices reached $2.96 billion in 2005. Fueled by explosive growth in high-value combination products, the market will increase at an average annual growth rate (AAGR) of 12.4% to more than $5.31 billion by 2010. This report:

• Analyzes the markets for medical device coatings and surface treatment technologies worldwide, by medical specialty and material, with forecasts through 2010.
• Examines the seven basic types of materials currently used to create coatings for more than 92,000 unique medical devices.
• Explains how the successful commercialization of engineered alloys, ceramics and polymers has transformed coatings from passive to active components in medical devices.
• Discusses changing medical needs that are accelerating the future demand for coated medical products.
• Reviews more than 200 patents and profiles key coating and medical device suppliers.

Point of Care (POC) testing revenue reached an estimated $5.07 billion in 2005 and is expected to grow at a 13.8% average annual growth rate (AAGR) through 2010, yielding sales of nearly $9.68 billion. This report contains:

• A detailed description of the point of care (POC) industry
• Estimates of the current and future market sizes through 2010
• Highlights of emerging and leading technologies
• A discussion of product segments
• A detailed analysis of the market's influences and predictions for the future of POC
• Company profiles and reviews of the market leaders and their business activities

The dental market is estimated at nearly $6.7 billion in 2005, up from $6.2 billion the previous year. It will reach nearly $9.4 billion in 2010, an average annual growth rate (AAGR) of 7%. This report contains:

• An overview of the issues, products, and forecasts in the dental market
• A detailed description of professional dental equipment and supplies
• Competitive analysis of the industry's key driving factors, inhibitors, and potential growth areas
• Analysis of the current and upcoming applications in various industry sectors, including pharmaceuticals, anesthetics, prophylactics, and restorative/cosmetic dentistry
• Discussion of the latest technological issues and developments, including the latest industry trends
• Company profiles for all the industry leaders and more.

The U.S. market for assistive technologies is projected to rise from $30.7 billion in 2005 to $39.4 billion in 2010, an AAGR (average annual growth rate) of 5.2%. This report contains:

• An overview of technologies used in disabled and elderly care products
• Discussion of conditions and applications addressed
• Analysis of product types
• Discussion of legal, regulatory, and insurance issues
• Discussion of patent and IP issues
• Market analysis, including market size and segmentation and projections through 2010
• Analysis of market drivers
• Discussion of the industry's size, structure, competition and market shares.

Sales for the blood and blood components segment and the plasma derived segment of the U.S. blood market will approach $6.6 billion in 2005 and are expected to approach $9.9 billion in 2010, rising at an average annual growth rate of 8.5%. The report contains coverage of:

• Structure and current market size of the blood industry with forecasts through 2010
• All aspects including: blood salvage, autologous donations, apheresis, fractionation and stem cells as well as major plasma products
• Blood usage patterns and trends
• Government and regulatory controls
• Impact of disease on the blood industry
• Major players and their relative market share and market potential
• Current product lines and examination of newly emerging products and technologies
• State of the international markets
• Newly issued patents relating to blood and disease screening.

The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate of 5.2% to $15.1 billion by 2010. This report contains:

• Full coverage of product segments including solid organs, experimental xenografts and artificial organs; tissue transplants and cell transplants
• Forecasts by product type and application through 2010, including supporting analyses for projections
• An overview of international markets
• Discussion of the industry's structure and the regulatory environment
• Profiles of leading companies involved including placement within the market and strategic analyses of available and emerging products.

The U.S. market for prosthetics, orthotics and cosmetic enhancement products is expected to increase from $6.8 billion in 2005 to $10.8 billion in 2010, at an average annual growth rate of 9.9%. This report contains:

• Discussion of major product types and applications, both commercial and developmental
• An overview of market size and segmentation, including historical data on sales by application and product type
• Market drivers and constraints detailed market projections through 2010
• Analysis of industry structure, competition and market shares
• Discussion of factors that may influence the long-term market for prosthetic and orthotics devices and cosmetic enhancement products.

The world market for drugs to treat mental, emotional and behavioral problems in children and adolescents is estimated at $13.4 billion in 2005 and is expected to rise at an average annual growth rate of 7.2% to $19 billion in 2010. This report contains:

• An overview of the behavioral and emotional disorders in children and adolescents
• Sales figures for the following categories of drugs: benzodiazepines, mood stabilizers, antipsychotics, SSRIs, tricyclic antidepressants, CNS stimulants and nonstimulants
• Market projections on their worldwide use to 2010
• Drug categorizations by disorder with sales figures for each
• Profiles of the companies selling these products
• Discussion of factors affecting markets as a result of regulatory issues.

The overall U.S. imaging equipment and auxiliary products market is estimated to be $7.9 billion in 2004 and is expected to increase at a 5.7% average annual growth rate to reach $10.4 billion by 2009. This report contains:

• A focus on the modalities generally considered part of the medical imaging industry, such as:
      o X-ray, including radiography and fluoroscopy
      o Computed tomography
      o Magnetic resonance imaging
      o Ultrasound
      o Nuclear medicine, including both single-photon emission studies and positron emission tomography
• A review of some of the newer imaging modalities
• Analysis of the industry's structure, regulatory environment and salient technological developments in each area
• Market forecasts for each type of product and application, and for geographical areas of the world through 2009
• Profiles of many of the leading companies in the industry.

The U.S. market for radiation-based therapy and therapeutic monitoring equipment is projected to rise at an average annual growth rate of 7.6% from $4 billion in 2004 to $5.7 billion in 2009. This report contains:

• Definitions of and milestones in the development of TR
• Examination of existing TR technologies and technologies under development
• Analysis of intellectual property and patent portfolios
• Analysis of current and potential TR applications
• Market forecasts for TR applications and end-user segments with the greatest commercial potential in the U.S. through 2009
• Analysis of the industry's structure and market shares.

The total U.S. market for reproductive technologies and products is estimated to be $6.5 billion in 2004. In 2009, revenues will likely reach $9.8 billion, rising at an average annual growth rate (AAGR) of 8.6%. This report contains:

• A review of male and female reproductive health
• An overview of standard pharmaceutical treatments, devices and technologies
• An analysis of market size in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception and sexual dysfunction with forecasts to 2009
• Market participants and current competitor market shares
• An investigation of pipeline products and technologies.

The combined worldwide market for four categories of adjunctive therapies is estimated at $1.7 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 39.2% to $8.8 billion in 2009. This report contains:

• An overview of the four categories
• Descriptions of the technologies involved and how these differ from existing and emerging technologies
• Discussion of the technology approaches undertaken by the various competitors, how current and emerging products are used, and industry and end-user response to these products
• Analysis of regulatory issues and legislation affecting use and marketing of products
• Market forecasts through 2009 for each category
• Profiles of selected competitors in each category.

The overall worldwide market for molecular (DNA) assays is expected to reach $7.3 billion in 2004 and will rise at an average annual growth rate of 11% to $12.6 billion in 2009. This report contains:

• An overview and definition of molecular tests and test applications
• Discussion of the interplay of advances in the Human Genome Project and pharmaceutical research
• Analysis of each technology and technological issues including the latest trends
• Current worldwide market status of each, its impact on future markets, and forecasts for growth through 2009
• An examination of influential factors such as technological developments, bioinformatics, patent issues and patient demographics
• Government regulations regarding the commercialization of molecular tests in major regions of the world
• Market and company market share estimates.

Fueled by stent revenues, U.S. catheter market sales were forecast to exceed $13.1 billion in 2003. Rising at an average annual growth rate of 12.3%, the market is expected to exceed $23 billion in 2009. This report contains:

• Analysis of underlying technological advances
• Discussion of product development by market segment
• Analysis of competition within each segment
• Complete patent analysis
• vDiscussion of strategic marketing actions
• Overview of regulations and standards relating to the industry
• vGrowth trends by segment with forecasts to 2009.

The global market for microelectronic medical implants is projected to be $11.9 billion in 2004 and to rise at an average annual growth rate of 22.1% to $32.3 billion in 2009. This report contains:

• An overview of major implant types and applications, both commercial and developmental
• Global market size and segmentation, including historical data on sales by application and implant type
• Discussion of market drivers and constraints
• Detailed market projections through 2009
• Industry structure, competition and market shares
• Analysis of factors that may influence the long-term market for microelectronic implants.

The combined worldwide market for cardiac markers, drug eluting stents, portable automated external defibrillators, cardiac resynchronization therapy plus angiogenesis/gene therapy products introduced during the forecast period (2003-2008), should reach $16 billion by 2008. This report contains:

• A comprehensive overview of one category of diagnostics, one category of therapeutics and three categories of devices that are, or will be revolutionizing the treatment of cardiovascular diseases
• A chapter on each of the five categories: cardiac markers, drug-eluting stents, automated exexternal defibrillators, cardiac resynchronization therapy and angiogenesis/gene therapy
• Full descriptions of the technologies involved and how these differ from existing and emerging technologies
• Analysis of the technological approaches undertaken by the various competitors and industry and end-user response to these products
• Regulatory issues and legislation affecting use and marketing of products
• Market forecasts for each category of product through 2008, and profiles of selected competitors in each category are included.

The total worldwide market for animal therapeutics and diagnostics was estimated at more than $15.6 billion in 2003 and by 2008 is likely to reach $19.6 billion, at an average annual growth rate of 4.7%. This report contains:

• A thorough evaluation of the animal therapeutic and diagnostic markets
• Market coverage worldwide, with special emphasis on U.S. trends and statistics
• Coverage of four segments: vaccines, pharmaceuticals, feed additives and diagnostics (point-of-care products are considered rapid tests or kits)
• Detailed information based on product categories, product use and forecasts
• Competitive analyses for each segment.

The total U.S. market for imaging reagents is expected to grow to $3.9 billion by 2008 at an average annual growth rate of 6.9%. This report contains:

• Discussion of the basic principles behind all types of imaging including x-rays, ultrasound, magnetic resonance, radiopharmaceuticals and ionic and nonionic
• Discussion of the regulations governing their use
• Analysis of medical imaging reagent markets over a five-year period with forecasts through 2008
• Overviews of the companies selling these products
• Analysis of the factors affecting markets for these products, and how those markets are likely to change.

The U.S. market will rise to $4.3 billion by 2008, at an average annual growth rate of 8.1%. This report covers the following topics:

• Major product types and applications, both commercial and developmental
• U.S. market size and segmentation, including historical data
• Market drivers and constraints
• Detailed U.S. market projections through 2008
• Factors that may influence the long-term market for patient monitoring devices, and
• Industry structure, competition and market shares.

The worldwide market for nanoscale devices and molecular modeling is expected to rise at an average annual growth rate of 27.5% from $400 million in 2002 to $1.37 billion in 2007. The report covers:

• Bioassays that use nanoscale components, including thin films and nanoparticles
• Nanotools applied to life science research, including atomic force microscopes and accessories
• Drugs and drug delivery systems that use nanoscale capsules, fullerenes or MEMS
• Fullerene objects, like nanotubes, as applied to medical devices
• Quantum dots as applied to bioanalytical systems
• vProspectives on artificial cells, organs and organisms
• Forecasts through 2007
• Major players and their profiles.

The U.S. market will reach $7.9 billion in 2008, up from $7.1 billion in 2003 and the global market will average 4.5%/year growth, reaching $23.6 billion in 2008. The report cover the following topics:

• Major product types and applications, both commercial and developmental
• U.S. market size by application, product type and end-user group
• Market drivers and constraints
• Detailed U.S. market projections through 2008
• Industry structure, competition and market shares
• The future for diagnostic reagents, chemicals and consumables.

The U.S. biocompatibles market will grow at a 7.7% average annual growth rate through 2008 to reach $11.9 billion. Specifically, the report includes:

• The changing biocompatible materials industry and end-user segments
• Market influences and predictions of the future shape of the market
• Trends within the market segments and their future outlook
• Business activities of market leaders in each segment
• Emerging and leading technologies likely to have an impact in the future
• An overview of the worldwide nature of the industry.

By 2007, the total revenues of protein array technologies will approach $336 million. This report includes:

• An overview of the market and a discussion of relevant scientific principles
• Analysis of government regulations
• Current and future market trends, with five year forecasts
• Importance of each new research method to the overall market
• Analysis of patents and their importance to the industry
• R&D in current and new protein array technologies
• Company directory.

U.S. MRCAS market will grow at more than 22% annually on average reaching $673 million by 2007. The report is organized around the following topics:

• Major types and applications of MRCAS
• Industry structure competition and market shares
• Market size and segmentation by application, product type and region
• Market drivers
• Detailed market projections through 2007
• Observations and conclusions regarding the future of the MRCAS market.

The U.S. and the global market for MIS devices and instruments are expected to reach $4.88 and $8.3 billion in 2007, respectively. The report is organized around the following topics:

• An overview of the market and a discussion of relevant scientific principles
• Major types and applications of minimally invasive surgical devices and instruments
• Market size and segmentation by application product type, and end-user group
• Industry structure and market drivers
• Detailed market projections through 2007
• Competition and market shares
• Conclusions regarding the future of minimally invasive devices and instruments.

U.S. sales are forecasted at an average annual growth rate of 9.3% through 2007. The most active segments are clinical lab, instruments and POC testing. This report:

• Describes the clinical diagnostic industry
• Profiles end-user segments and their changing demands
• Analyzes market influences and predicts the changes that will shape the future clinical diagnostics market through 2007
• Discusses trends and future outlook within the market segments
• Reviews business activities of market leaders in each segment
• Highlights emerging and leading technologies that likely will impact in the future
• Provides profiles of leading players.

The U.S. telemedicine market is expected to show a 9.7% average annual growth rate from their current level of $4.33 billion, to reach $6.9 billion by 2007. This report provides information on all telemedical technologies and services, including:

• Infrastructure hardware
• Software and networking equipment
• Telecom devices, as used for delivery of medical services, education
• Medical equipment procurement
• Other medically-related commercial transactions, such as insurance
• Historic and emerging U.S. demographic and use trends
• Discussion of international aspects
• Market forecasts for products and technologies through 2007.

The U.S. tissue and organ transplantation is expected to reach $20.5 billion by 2007 at an average annual rate of 3.5%. This BCC report offers:

• Analysis of product segments: solid organs, experimental xenografts and artificial organs, tissue and cell transplants, fetal cells, stem cells, altered cancer cells, immunosuppressive agents and tissue diagnostics
• Market segments with projections covering 2002 to 2007
• Industry structure, regulatory environment
• Profiles of leading companies.

The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007. This report provides coverage of:

• the seven major diabetes drug classes: insulin, biguanides, sulfonylureas, a-glucosidase inhibitors, thiazolidinediones, meglitinides and d-phenylalanine derivatives
• insulin pumps and glucose monitoring devices
• upcoming classes of diabetes drugs: ppara/g agonists, pparg agonist (non-thiazolinedione), glycogen phosphorylase inhibitors, glucagonlike peptides, and dipeptidylpeptidase IV inhibitors
• product market trends and forecasts by product type
• the international market, industry structure and regulatory environment.

Sales of imaging equipment, for which the U.S. market is projected to reach $6.1 billion in 2002, are expected to grow at a 3.4% AAGR, reaching $7.2 billion (in 2002 dollars) by 2007. This report focuses provides coverage of:

• The modalities generally considered part of the medical imaging industry, including Xray, computed tomography, magnetic resonance imaging, ultrasound and nuclear medicine
• Newer imaging modalities such as electrical impedance scanning and optical coherence tomography
• Medical imaging markets for each type of product and application, and for geographical areas of the world, with forecasts through 2007
• Leading companies in the industry and the structure of the industry.

This report, The Market for Prescription Antiviral Drugs, provides the reader with a detailed analysis of the current and future international markets and trends for an $8+ billion market. Market figures are provided for 1998, 1999, 2000 and 2001, with forecasts provided to 2006. The report includes product descriptions, demographics and statistical information, market analyses, competitor market shares, new developments, and leading company profiles. The reader will have an understanding of the current market drivers and innovations that are influencing market trends.

The total U.S. market for human reproductive technologies reached $6.9 billion in 2001. It is expected to rise at an AAGR (average annual growth rate) of 10.1% to $11 billion in 2006. This report provides technology and usage trends, markets and forecasts, and manufacturer profiles and pipelines for the following areas of reproductive technology:

• Fertility Enhancement (pharmaceuticals and procedures)
• Contraception and Abortion (prescription pharmaceuticals and devices)
• Reproduction Related Diagnostics (including fertility status and monitoring diagnostics)

MDKs are analytical test kits packaged for use on a single-test basis to test for a wide variety of substances. MDKs bring diagnostic testing capabilities to a variety of end-users, ranging from sophisticated high-technology clinical research and veterinary laboratories to individuals performing self-testing in their own homes. This study defines the MDK market and provides detailed information, including the products that comprise the MDK industry, the emerging and current MDK technologies, and an analysis of these technologies and their impact on future products and market growth. Also discussed are the market structure and current market size with forecasts through 2005 with specific emphasis on each segment, the current market dynamics and trends, emerging marketing practices such as strategic alliances and mergers, effect of external market forces such as insurance, regulatory and economic issues and increased incidence of disease, the internal aspects of the industry, and the specific opportunities for industry participants and industry suppliers.

Cancer remains the second-leading cause of death in the industrialized world, but the disease continues to be underserved by effective therapeutic agents. Further, many of the available agents act systemically and therefore have side effects that range from uncomfortable to life threatening. At the end of 2000, there were over 350 drugs in development for the treatment of various cancers, more than for any other disease category. Of these, more than 40 were in Phase III trials. This report discusses four primary categories of currently available cancer agents: cytotoxics, biologics (excluding vaccines), adjunct therapies and innovative therapies. Innovative therapies include such products as monoclonal antibodies, vaccines and gene therapy. Market forecasts and trends are provided for these categories. Extended discussion is provided on new technologies involved in the treatment of cancer, such as angiogenesis inhibitors, matrix metalloproteinase inhibitors, signal transduction inhibitors, antibodies to surface markers and growth factors, gene therapies and vaccines. The competitive environment is examined, with a special focus on how new products and technologies as well as acquisitions and mergers are likely to reshuffle the leading manufacturers in the cancer arena. Profiles are provided of current market leaders as well as companies with innovative products poised to enter the sector during the forecast period.

This BCC report provides a comprehensive analysis of the structure and market size of the U.S. blood collection/transfusion industry and its related areas of autologous donations, plasmapheresis/fractionation, bone marrow therapies, blood salvaging , blood substitutes and animal transfusion. The study defines market size and market shares, describes structure and dynamics and profiles the major players with forecasts through 1998 for all segments. Topics addressed include: usage trends, regulatory controls, impact of disease on the industry, major players and their market shares and potential, current and emerging products and technologies and opportunities for development and commercialization of new or alternative products and services.

The baby-boom generation is becoming middle-aged, a period when osteoporosis and arthritis begin to take their toll on bones and joints. It might seem to be a great period for the makers of orthopedic devices, like knee or spinal implants. However, several different varieties of drugs, from biphophonates to synthetic peptides, not only seem to prevent osteoporosis but increase bone density as well. A host of new arthritis drugs are also coming on the scene. Tissue implants may replace the titanium and plastic varieties. Gene therapy is being proposed for common injuries such as bone fractures. This report examines the state of technology within the orthopedic industry, and estimates the size of markets over the next five years for treatments for bone and joint disorders. All the major orthopedic companies and many of the minor ones are profiled. We handicap the prospects for various orthopedic treatments and give or view of the shape of the industry on the future.

The use of molecular and FISH cytogenetic methods in genetic disease testing in the United States and internationally is growing. In 2005, domestic and international molecular methods are forecasted to represent 64.0% and 11.9% of the genetic disease testing applications market, while domestic and international cytogenetic procedures represent 17.4% and 6.6% of the sales market. The average annual growth rates of domestic and international molecular and cytogenetic procedures are 10.1%, 7.7%, 12.3% and 13.0%, respectively. This report provides data analysis and forecasts through the year 2005 on:

• market composition and dynamics
• market size
• market participants with related market shares
• current and emerging technologies
• impact of and trends in legal and government regulations
• international aspects.

This BCC report assesses the impact of new technologies and new products on sales of pain management pharmaceuticals and pain management devices over the next 5 years and beyond. The report focuses on the various pharmaceutical preparations available, new entrants projected to become dominant in the coming years and emerging products. The report provides a comprehensive overview of the fledgling field of pain management and the common medical treatments used. Markets are divided according to product category. The report provides a forward look at developments now in progress and being implemented in the pain management arena. Analyses of the various product market categories and competitors, as well as insights and explorations of critical issues involving pain management, are addressed. Alternative methods of pain management treatment are discussed and pain management clinics are defined. Competitor profiles such as Abbott, ADM Tronics, AstraZeneca, Bayer, Medtronic and others are also included.

Medical imaging is a most important, rapidly-developing diagnostic tool. The diagnostic differentiation between organs in the various techniques (X rays, MRI, Ultrasound, etc.) is made possible by the use of specific chemicals -- contrast agents. This BCC report describes the technological and medical aspects of the important contrast agents in use and their specific applications. Producers are referred to, and the world-wide market is analyzed. Manufacturing aspects and properties of the agents, as well as development trends, are discussed.

Medical imaging is undergoing a revolution from analog imaging to digital imaging. This report covers the changing medical imaging field from conventional x-ray to new modalities, such as Magnetic Resonance Imaging (MRI). Radiology departments in hospitals are being renamed Diagnostic Imaging Departments to indicate the new modalities. The new diagnostic imaging departments will be integrated via the Picture Archival and Communications System (PACS) from the imaging system, to viewing on workstations, and data storage on laser disks. As a result, the radiologist will be able to compare images from different modalities at one time on a workstation.